MASAC Issues Advisory on Possible Increased Risk of Inhibitors to Factor VIII

The Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation has issued a Medical Advisory concerning the risk of inhibitor development from a recombinant factor VIII product. Three recently published research studies found higher rates of inhibitor antibody formation in previously untreated patients who were given Kogenate FS / Helixate NexGen. You can read the MASAC Advisory here: https://www.hemophilia.org/Newsroom/Medical-Advisories/Medical-Advisory-417-Assessment-of-Possible-Increased-Risk-of-Inhibitors-in-Specific-Recombinant-FVIII-Replacement-Concentrates-in-Previously-Untreated-Patients-PUPS.